Revenue Recognition - Schedule of Revenue by Product (Details) - USD ($) $ in Millions		3 Months Ended															12 Months Ended
		Dec. 31, 2020	[1]	Sep. 30, 2020	[2]	Jun. 30, 2020	[3]	Mar. 31, 2020	Dec. 31, 2019	[4]	Sep. 28, 2019	[5]	Jun. 29, 2019	[6]	Mar. 30, 2019	[7]	Dec. 31, 2020		Dec. 31, 2019		Dec. 31, 2018
Disaggregation of Revenue [Line Items]
Net sales		$ 1,289.5		$ 1,213.7		$ 1,219.1		$ 1,341.0	$ 1,322.8		$ 1,191.1		$ 1,149.0		$ 1,174.5		$ 5,063.3	[8]	$ 4,837.4	[8]	$ 4,731.7	[8]
CSCA
Disaggregation of Revenue [Line Items]
Net sales	[9]																2,693.0		2,487.7		2,411.6
CSCA | Upper respiratory
Disaggregation of Revenue [Line Items]
Net sales	[9]																489.5		515.2		492.5
CSCA | Digestive health
Disaggregation of Revenue [Line Items]
Net sales	[9]																452.6		413.9		403.6
CSCA | Pain and sleep-aids
Disaggregation of Revenue [Line Items]
Net sales	[9]																424.7		383.6		388.1
CSCA | Nutrition
Disaggregation of Revenue [Line Items]
Net sales	[9]																387.4		394.4		432.4
CSCA | Healthy lifestyle
Disaggregation of Revenue [Line Items]
Net sales	[9]																348.5		352.4		333.6
CSCA | Oral self-care
Disaggregation of Revenue [Line Items]
Net sales	[9]																284.6		106.4		0.0
CSCA | Skincare and personal hygiene
Disaggregation of Revenue [Line Items]
Net sales	[9]																191.8		182.9		164.1
CSCA | Vitamins, minerals and supplements
Disaggregation of Revenue [Line Items]
Net sales	[9]																27.0		28.6		26.1
CSCA | Animal health
Disaggregation of Revenue [Line Items]
Net sales	[9]																0.0		43.7		93.9
CSCA | Other CSCA
Disaggregation of Revenue [Line Items]
Net sales	[10]																86.9		66.6		77.3
CSCI
Disaggregation of Revenue [Line Items]
Net sales																	1,395.2		1,382.2		1,399.3
CSCI | Upper respiratory
Disaggregation of Revenue [Line Items]
Net sales																	255.1		276.8		276.5
CSCI | Digestive health
Disaggregation of Revenue [Line Items]
Net sales																	26.5		27.1		29.5
CSCI | Pain and sleep-aids
Disaggregation of Revenue [Line Items]
Net sales																	190.4		167.9		170.0
CSCI | Healthy lifestyle
Disaggregation of Revenue [Line Items]
Net sales																	165.4		173.8		180.7
CSCI | Oral self-care
Disaggregation of Revenue [Line Items]
Net sales																	97.8		51.2		8.9
CSCI | Skincare and personal hygiene
Disaggregation of Revenue [Line Items]
Net sales																	351.8		371.6		396.5
CSCI | Vitamins, minerals and supplements
Disaggregation of Revenue [Line Items]
Net sales																	201.0		180.2		187.2
CSCI | Other CSCI
Disaggregation of Revenue [Line Items]
Net sales	[11]																107.2		133.6		150.0
RX
Disaggregation of Revenue [Line Items]
Net sales																	$ 975.1		$ 967.5		$ 920.8

[1] Includes change in financial assets of $122.3 million and impairment charges of $144.4 million.

[2] Includes impairment charges of $202.4 million, change in financial assets of $22.2 million and loss on early debt extinguishment of $20.0 million.

[3] Includes Rosemont Pharmaceuticals business pre-tax loss of $21.1 million.

[4] Includes impairment charges of $141.6 million.

[5] Includes animal health divestiture pre-tax gain of $71.7 million, Ranitidine market withdrawal charges of $18.4 million, acquisition-related charges and contingent consideration adjustments of $18.1 million, and impairment charges of $10.9 million.

[6] Includes impairment charges of $27.8 million and restructuring charges and other termination benefits of $12.2 million.

[7] Includes change in financial assets of $10.4 million.

[8] The net sales by geography is derived from the location of the entity that sells to a third party.

[9] Includes net sales from our OTC contract manufacturing business.

[10] Consists primarily of diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.

[11] Consists primarily of liquid licensed products, our distribution business and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.